Andere Sprachen Avenue Therapeutics, Inc.

Aktien

A40BWJ

US05360L4032

ATXI

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 01.05.2024			% 5 Tage	% 1. Jan.
4,76 ^USD	-4,99 %		-32,70 %	-60,58 %

18.03.	Avenue Therapeutics, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
22.02.	Avenue Therapeutics, Inc. kündigt Veröffentlichung in Drug Development Research an, die die ersten präklinischen Daten von BAER-101 in einem translationalen Modell der Absence-Epilepsie hervorhebt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds	29.04.
Avenue Therapeutics Announces Reverse Stock Split	24.04.
Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024	26.03.
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024	25.03.
Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18.03.
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights	18.03.
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq	15.03.
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting	11.03.
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy	22.02.
Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy	22.02.
Certain Stock Options of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	01.02.
Certain Warrants of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	01.02.
Certain Common Stock of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	01.02.
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference	11.01.
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	05.01.
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds	05.01.
Top Midday Gainers	04.01.
Avenue Therapeutics Shares Rise 68% After FDA Agreement for Tramadol Study	04.01.
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol	04.01.
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy	03.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Avenue Therapeutics, Inc.

Aktien

A40BWJ

US05360L4032

ATXI

Andere Sprachen

Filter